立体定向体部放射治疗对寡转移性乳腺癌全身治疗线改变的影响。
Impact of stereotactic body radiation therapy on systemic therapeutic line change in oligometastatic breast cancer.
作者信息
Leblanc Julie, de Nonneville Alexandre, Nicolas Camille, Gonçalves Anthony, Favrel Véronique, Tyran Marguerite, Guenole Morgan, Varela Leonel, Gonzague Laurence, Tallet Agnès, Petit Claire
机构信息
Aix-Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, Department of Radiotherapy, CRCM, Marseille, France.
Aix-Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, Department of Medical Oncology, CRCM, Marseille, France; Aix-Marseille Univ, CNRS, INSERM, CRCM, Marseille, France.
出版信息
Breast. 2025 Jul 21;83:104546. doi: 10.1016/j.breast.2025.104546.
• SBRT is widely used in oligometastatic breast cancer despite limited evidence. • SBRT delayed systemic therapeutic line change by over 1 year in our cohort. • Our study may help to identify patients most likely to benefit from SBRT. • SBRT is a well-tolerated treatment with limited toxicity. • Randomized trials are needed to assess the benefit of SBRT in terms of survival.
• 尽管证据有限，但立体定向体部放疗（SBRT）仍广泛应用于寡转移乳腺癌。
• 在我们的队列中，SBRT将全身治疗线的改变推迟了1年多。
• 我们的研究可能有助于确定最有可能从SBRT中获益的患者。
• SBRT是一种耐受性良好、毒性有限的治疗方法。
• 需要进行随机试验来评估SBRT在生存方面的益处。
Zotero 插件